Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer.

Int J Urol · 2024 · PMC11524110 · PMID 38318663

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a marked trendno p-value reported

46 , 47 Regimens combining VEGFR‐TKIs and ICIs for the treatment of mRCC did not show a marked trend toward an increased frequency of proteinuria with the addition of ICIs (Table 2 ).

also in 422 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.